US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

5.730 -1.820 (-24.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nexalin Technology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
(NXL) - Analyzing Nexalin Technology's Short Interest ↗
 
Via Benzinga
News headline image
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO Clarity™ neurostimulation device integrated... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Friday's pre-market session: top gainers and losers ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients ↗
Nexalin says the study published in the Journal of Alzheimer's Disease shows DIFS may enhance cognition in mild Alzheimer's patients. 
Via Benzinga
NASDAQ Stocks Under $1 to Watch in October 2024: LGCB, KAVL, NXL, NXU, FAMI
Via AB Newswire
Topics Economy Electric Vehicles
< Previous 1 2 3 4 5 6 7 8 9 10 Next >